Literature DB >> 16140506

NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder.

Carla Toro1, J F W Deakin.   

Abstract

Much interest has focussed on glutamate and the N-Methyl-D-Aspartate (NMDA) glutamate receptor in the pathogenesis of schizophrenia. A number of studies have reported abnormal gene transcription of various glutamate receptor subtypes in the hippocampus including the NMDA receptor. However, corresponding protein levels in subregions of the hippocampus have not yet been investigated. We have used immunoautoradiographical techniques to assess the expression of the obligatory NMDA receptor subunit NR1 and an associated post-synaptic density protein PSD-95 in the hippocampal dentate gyrus and orbitofrontal cortex (OFC) in schizophrenia and mood disorder. Optical density measures from film autoradiographs revealed no changes in NR1 or PSD-95 in the OFC or dentate hilus, however a decrease in PSD-95 was found in the dentate molecular layer in both schizophrenia and bipolar disorder relative to major depression. These findings were unrelated to antipsychotic or mood stabilizer drug treatment. The dentate molecular layer contains the dendritic trees of granule cells and is the target of major excitatory afferent inputs from associative cortical, parahippocampal and hippocampal regions. A reduction in PSD-95 at glutamate synapses of the molecular layer may have a deleterious impact on information flow to other hippocampal regions via granule cells and their projecting mossy fibres. A down-regulation of PSD-95 in schizophrenia and bipolar disorder may also relate to disease mechanisms of psychosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140506     DOI: 10.1016/j.schres.2005.07.003

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  55 in total

Review 1.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 2.  Receptor-associated proteins and synaptic plasticity.

Authors:  Emile G Bruneau; Jose A Esteban; Mohammed Akaaboune
Journal:  FASEB J       Date:  2008-10-31       Impact factor: 5.191

Review 3.  Overview of glutamatergic neurotransmission in the nervous system.

Authors:  Mark J Niciu; Benjamin Kelmendi; Gerard Sanacora
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

4.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

5.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

7.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

Review 8.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia.

Authors:  Min-Chih Cheng; Chao-Lin Lu; Sy-Ueng Luu; Ho-Min Tsai; Shih-Hsin Hsu; Tzu-Ting Chen; Chia-Hsiang Chen
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

10.  PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation.

Authors:  Peihua Sun; Jingru Wang; Weihua Gu; Wei Cheng; Guo-zhang Jin; Eitan Friedman; Jie Zheng; Xuechu Zhen
Journal:  Cell Res       Date:  2009-05       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.